

Christophe Glorieux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8112011/publications.pdf>

Version: 2024-02-01

30
papers

1,406
citations

516215

16
h-index

476904

29
g-index

30
all docs

30
docs citations

30
times ranked

2507
citing authors

#	ARTICLE	IF	CITATIONS
1	Catalase, a remarkable enzyme: targeting the oldest antioxidant enzyme to find a new cancer treatment approach. <i>Biological Chemistry</i> , 2017, 398, 1095-1108.	1.2	388
2	Regulation of catalase expression in healthy and cancerous cells. <i>Free Radical Biology and Medicine</i> , 2015, 87, 84-97.	1.3	190
3	Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. <i>Biochemical Pharmacology</i> , 2011, 82, 1384-1390.	2.0	119
4	Overexpression of GRP94 in breast cancer cells resistant to oxidative stress promotes high levels of cancer cell proliferation and migration: Implications for tumor recurrence. <i>Free Radical Biology and Medicine</i> , 2012, 52, 993-1002.	1.3	78
5	Hsp90 Is Cleaved by Reactive Oxygen Species at a Highly Conserved N-Terminal Amino Acid Motif. <i>PLoS ONE</i> , 2012, 7, e40795.	1.1	54
6	Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study. <i>Investigational New Drugs</i> , 2011, 29, 891-900.	1.2	50
7	Intracellular ATP levels determine cell death fate of cancer cells exposed to both standard and redox chemotherapeutic agents. <i>Biochemical Pharmacology</i> , 2011, 82, 1540-1548.	2.0	45
8	Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells. <i>Molecular Oncology</i> , 2017, 11, 358-372.	2.1	43
9	Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling. <i>Redox Biology</i> , 2021, 38, 101780.	3.9	42
10	Chromatin remodeling regulates catalase expression during cancer cells adaptation to chronic oxidative stress. <i>Free Radical Biology and Medicine</i> , 2016, 99, 436-450.	1.3	40
11	AICAR induces Nrf2 activation by an AMPK-independent mechanism in hepatocarcinoma cells. <i>Biochemical Pharmacology</i> , 2014, 91, 168-180.	2.0	38
12	Catalase down-regulation in cancer cells exposed to arsenic trioxide is involved in their increased sensitivity to a pro-oxidant treatment. <i>Cancer Cell International</i> , 2018, 18, 24.	1.8	38
13	Catalase expression in MCF-7 breast cancer cells is mainly controlled by PI3K/Akt/mTor signaling pathway. <i>Biochemical Pharmacology</i> , 2014, 89, 217-223.	2.0	37
14	Overexpression of NAD(P)H:quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones. <i>Life Sciences</i> , 2016, 145, 57-65.	2.0	30
15	Loss of mitochondrial aconitase promotes colorectal cancer progression via SCD1-mediated lipid remodeling. <i>Molecular Metabolism</i> , 2021, 48, 101203.	3.0	22
16	Evaluation of Potential Mechanisms Controlling the Catalase Expression in Breast Cancer Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-10.	1.9	21
17	Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy. <i>Journal of Hematology and Oncology</i> , 2022, 15, 30.	6.9	19
18	Oncogenic K-ras Induces Mitochondrial OPA3 Expression to Promote Energy Metabolism in Pancreatic Cancer Cells. <i>Cancers</i> , 2020, 12, 65.	1.7	18

#	ARTICLE	IF	CITATIONS
19	Cancer Cell Sensitivity to Redox-Cycling Quinones is Influenced by NAD(P)H: Quinone Oxidoreductase 1 Polymorphism. <i>Antioxidants</i> , 2019, 8, 369.	2.2	15
20	Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer. <i>Oncogene</i> , 2021, 40, 5880-5892.	2.6	15
21	The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer. <i>Cancers</i> , 2021, 13, 4426.	1.7	15
22	Regulation of CD137 expression through Kâ€Ras signaling in pancreatic cancer cells. <i>Cancer Communications</i> , 2019, 39, 1-11.	3.7	14
23	Targeting hsp90 family members: A strategy to improve cancer cell death. <i>Biochemical Pharmacology</i> , 2019, 164, 177-187.	2.0	14
24	Impact of <i>Nrf2</i> on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells <i>in vitro</i> and <i>in vivo</i> . <i>Free Radical Research</i> , 2018, 52, 661-671.	1.5	13
25	Glucose-regulated protein of 94 kDa contributes to the development of an aggressive phenotype in breast cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 115-120.	2.5	13
26	CD137 expression in cancer cells: regulation and significance. <i>Cancer Communications</i> , 2019, 39, 70.	3.7	11
27	Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. <i>Journal of Advanced Research</i> , 2022, 40, 109-124.	4.4	10
28	Diverse effects of chemotherapeutic agents on immune cell function and implications in immunochemotherapy. <i>Cancer Communications</i> , 2021, 41, 432-435.	3.7	8
29	Vitamin C (Ascorbate) and Redox Topics in Cancer. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 1157-1175.	2.5	6
30	Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2138444.	2.8	0